Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.3% – Here’s What Happened

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 130,023 Arbutus Biopharma Corporation $ABUS

Bank of America Corp DE Has $7.58 Million Stock Position in Arbutus Biopharma Corporation $ABUS

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer

Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GE HealthCare expands breast imaging portfolio with Invenia ABUS Prime and launch of ABUS StreamVue

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma: Moderna Validates My IP Bull Case